

# JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

NCT06701656

---

Status	RECRUITING
Phase	Phase 2
Sponsor	PPD Development, LP
Enrollment	200 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- ARDS Severity of mild, moderate or severe, based on PaO<sub>2</sub>/FiO<sub>2</sub> or SpO<sub>2</sub>/FiO<sub>2</sub> assessment at the time of randomization.

### Exclusion (18)

- Participant has a known allergy or hypersensitivity to the active substance/excipients, or Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies
- Participant with established cirrhosis and Child-Pugh Score of 7 or greater
- Participant was dialysis-dependent prior to hospitalization. Participant must have a urine dipstick for proteinuria  $\leq 2+$
- The hospitalized participant has a history or currently experiencing the following:
- Participant must not have an international normalized ratio (INR)  $>1.5$  and/or aPTT  $>1.5 \times$  upper limit of normal (ULN) within 7 days prior to initiation of study treatment for participants not receiving anticoagulation. For participants on full dose oral or parenteral anticoagulants for therapeutic purposes the INR and/or activated partial thromboplastin time (aPTT) must be within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the participant on a stable dose of anticoagulants for  $\geq 2$  weeks prior to initiation of study treatment.

... and 13 more (see full listing online)

## Locations (36 total)

---

University of Alabama Hospital, Birmingham, Alabama, United States  
Community Regional Medical Center, Fresno, California, United States  
Long Beach Memorial Medical Center, Long Beach, California, United States  
... and 33 more locations